SAN GROUP BIOTECH USA, INC. – Trademark Portfolio
Entity Type: 03
SAN GROUP BIOTECH USA, INC. owns a portfolio of 21 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as DART, XENA, BIOLINK, GARGOIL, and TRIGGRR. Of these, 19 are registered. The portfolio spans 3 Nice Classification classes, led by Class 1 (Chemicals) and Class 5 (Pharmaceuticals). Headquartered in VISTA, CA.
1260 AVENIDA CHELSEA
VISTA, CA 92081
Showing of trademarks Trademarks
Trademark Classifications
SAN GROUP BIOTECH USA, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does SAN GROUP BIOTECH USA, INC. have?
SAN GROUP BIOTECH USA, INC. has 21 U.S. trademarks filed with the USPTO. Of these, 19 registered, 1 abandoned, 1 cancelled.
What trademark classes does SAN GROUP BIOTECH USA, INC. file in?
SAN GROUP BIOTECH USA, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are SAN GROUP BIOTECH USA, INC.'s most well-known trademarks?
SAN GROUP BIOTECH USA, INC.'s registered trademark portfolio includes well-known marks such as DART, XENA, BIOLINK, GARGOIL, and TRIGGRR. These are among 19 currently registered trademarks in the portfolio.
What is SAN GROUP BIOTECH USA, INC.'s trademark registration success rate?
SAN GROUP BIOTECH USA, INC. has a 90% trademark registration rate, with 19 out of 21 resolved applications resulting in successful registration. Currently, 0 applications are pending review.